Last reviewed · How we verify
NCT05453032
The Effect of Non Invasive Brain Stimulation on Impulsivity in Borderline Personality Disorder
NA trial testing NeuroConn in Borderline Personality Disorder in 13 participants. Completed in 20 July 2022.
30 March 2022
Quick facts
| Lead sponsor | Ciusss de L'Est de l'Île de Montréal |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 10 May 2021 |
| Primary completion | 30 March 2022 |
| Estimated completion | 20 July 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- NeuroConn
Conditions studied
- Borderline Personality Disorder — all drugs for Borderline Personality Disorder →
Sponsor
Ciusss de L'Est de l'Île de Montréal — full company profile →
Who can join
Adults 18 to 65, any sex, with Borderline Personality Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A pilot study to examine the effects of Non-Invasive Brain stimulation on impulsive behaviour in patients diagnosed with Borderline Personality Disorder. patients who received the neurostimulation sessions will be enrolled in short term psychotherapy (3-month)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05453032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Borderline Personality Disorder
Currently open trials in the same condition.
- NCT06458933 — Testing Interventions for Borderline Personality Disorder. · Phase 2 · recruiting
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT07119541 — Testing an Alliance-Focused Dialectical Behaviour Therapy Training for Borderline Personality Disorder · NA · active not recruiting
- NCT06446765 — Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder · Phase 2 · recruiting
- NCT07197502 — Treatment of Borderline Personality Disorder With rTMS · NA · recruiting
Other Ciusss de L'Est de l'Île de Montréal trials
Trials by the same sponsor.
- NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
- NCT06500143 — Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery · completed
- NCT06522698 — Optimizing Research Data Acquisition With Smart Pill Bottles · NA · not yet recruiting
- NCT06522711 — Virtual Reality for Anxiolysis and Pharmacological Sparing · NA · not yet recruiting
- NCT07112261 — Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05453032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ciusss de L'Est de l'Île de Montréal
- Last refreshed: 14 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05453032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing